DEGRO practical guidelines for palliative radiotherapy of breast cancer patients: Brain metastases and leptomeningeal carcinomatosis

Strahlentherapie und Onkologie

Volumn 186, Issue 2, 2010, Pages 63-69

  Feyer, Petra ^a   Sautter Bihl, Marie Luise ^b   Budachs, Wilfried ^c   Dunst, Jürgen ^d   Haase, Wulf ^e   Harms, Wolfgang ^f   Sedlmayer, Felix ^g   Souchon, Rainer ^h   Wenz, Frederik ⁱ   Sauer, Rolf ^j  

^a VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^b Municipal Hospital   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e St Vincentius Kliniken   (Germany)

^f St Claraspital AG   (Switzerland)

^g UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j UNIVERSITY HOSPITAL ERLANGEN   (Germany)

more..

Author keywords

Brain metastases; Breast cancer; Leptomeningeal carcinomatosis; Palliative treatment; Radiotherapy

Indexed keywords

CAPECITABINE; CORTICOSTEROID; CYTARABINE; DEXAMETHASONE; METHOTREXATE; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; TRASTUZUMAB;

BRAIN EDEMA; BRAIN METASTASIS; BREAST CANCER; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; DRUG EFFICACY; HUMAN; INTRACRANIAL HYPERTENSION; KARNOFSKY PERFORMANCE STATUS; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDICAL SOCIETY; MEDLINE; NEUROLOGIC DISEASE; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; REVIEW; STEREOTACTIC RADIOSURGERY; SURVIVAL TIME; SYMPTOMATOLOGY; ADJUVANT CHEMOTHERAPY; ARTICLE; BRAIN TUMOR; BREAST TUMOR; COOPERATION; DISEASE FREE SURVIVAL; FEMALE; INTERDISCIPLINARY COMMUNICATION; METASTASIS; MORTALITY; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; PATIENT CARE; RADIOSURGERY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SKULL IRRADIATION;

BRAIN NEOPLASMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; COOPERATIVE BEHAVIOR; CRANIAL IRRADIATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERDISCIPLINARY COMMUNICATION; KARNOFSKY PERFORMANCE STATUS; MENINGEAL CARCINOMATOSIS; PALLIATIVE CARE; PATIENT CARE TEAM; PROGNOSIS; RADIOSURGERY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 77449083845     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-010-2100-y     Document Type: Review

References (72)

1. 1. Andrews D, Scott C, Sperduto P, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004;363:1665-1672 (Pubitemid 38670323)
2. 2. Antonadou D, Paraskevaidis M, Sarris G, et al. Phase II radomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002;20:3644-3650 (Pubitemid 34983224)
3. 3. Astner ST, Nieder C, Stock K, et al. Carcinomatous meningitis appearing as acoustic neuromas. Strahlenther Onkol 2007;183:279-283 (Pubitemid 46725988)
4. AWMF online Leitlinien der Deutschen Gesellschaft für Neurologie: Meningeosis neoplastica (http://www.uni-duesseldorf.de/WWW/AWMF/ll/030-060.htm).
5. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004;22:2865-2872
6. 6. Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases from solid tumor: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 1998;82:1756-1763 (Pubitemid 28208928)
7. 7. Boogerd W, Dorresteijn LD, van der Sande JJ, et al. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 2000;55:117-119 (Pubitemid 30461010)
8. Boogerd W, Hart AA, van der Sande JJ, et al. Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 1991;67:1685-1695
9. 9. Boogerd W, van den Bent MJ, Koehler PJ, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 2004;40:2726-2733 (Pubitemid 39574724)
10. 10. Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastasis: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1980;6:1-9. (Pubitemid 10103009)
11. 11. Borgelt B, Gelber R, Larson M, et al. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1981;7:1633-1638 (Pubitemid 12212604)
12. Chamberlain MC. Neoplastic meningitis. J Clin Oncol 2005;23:3605-3613
13. Chamberlain MC. Neoplastic meningitis. Oncologist 2008;13:967-977
14. Chamberlain MC, Johnston SK, Glantz MJ. Neoplastic meningitis-related prognostic significance of the Karnofsky performance status. Arch Neurol 2009;66:74-78
15. Chamberlain MC, Kormanik PR. Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy. J Neurooncol 1997;35:55-64.
16. Chang EL, Maor MH. Standard and novel radiotherapeutic approaches to neoplastic meningitis. Curr Oncol Rep 2003;5:24-28
17. Cole BF, Glantz MJ, Jaeckle KA, et al. Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer 2003;97:3053-3060
18. DeAngelis LM, Boutros D. Leptomeningeal metastasis. Cancer Invest 2005;23:145-154
19. DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology 1989;39:789-796
20. Fizazi K, Asselain B, Vincent-Salomon A, et al. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer 1996;77:1315-1323
21. 21. Gaspar L, Scott C, Murray K, et al. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 2000;47:1001-1006 (Pubitemid 30345599)
22. 22. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745-751 (Pubitemid 27181303)
23. 23. Gelber R, Larson M, Borgelt B, et al. Equivalence of radiation schedules for the palliative treatment of brain metastases in patients with favorable prognosis. Cancer 1981;48:1749-1753 (Pubitemid 11022876)
24. 24. Glantz M, Cole B, Forsyth P, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;54:1886-1893 (Pubitemid 30327107)
25. Glantz MJ, Cole BF, Recht L, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 1998;16:1561-1567
26. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999;5:3394-3402
27. Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev 1999;25:103-119
28. 28. Hedde JP, Neuhaus T, Schüller H, et al. A phase I/II trial of topotecan and radiation therapy for brain metastases in patients with solid tumors. Int J Radiat Oncol Biol Phys 2007;68:839-844 (Pubitemid 46830844)
29. 29. Hermann B, Hültenschmidt B, Sautter-Bihl ML. Radiotherapy of the neuroaxis for palliative treatment of leptomeningeal carcinomatosis. Strahlenther Onkol 2001;177:195-199 (Pubitemid 32303513)
30. 30. Herrlinger U, Förschler H, Küker W, et al. Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J Neurol Sci 2004;223: 167-178 (Pubitemid 39164359)
31. Hicks DG, Short SM, Prescott NL, et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK 5/6, and overexpress HER 2 or EGFR. Am J Surg Pathol 2006;30:1097-1104
32. International Commission on Radiation Units and Measurements. ICRU report 50: prescribing, recording, and reporting photon beam therapy. Washington: International Commission on Radiation Units and Measurements, 1993.
33. Jereczek-Fossa BA, Kowalczyk A, D'Onofrio A, et al. Three-dimensional conformal or stereotactic reirradiation of recurrent, metastatic or new primary tumors. Analysis of 108 patients. Strahlenther Onkol 2008;184:36-40.
34. Kim L, Glantz MJ. Neoplastic meningitis. Curr Treat Options Oncol 2001;2:517-527
35. 35. Kondziolka D, Patel A, Lunsford D, et al. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 1999;45:427-434 (Pubitemid 29408559)
36. Kortmann RD, Bamberg M. Zentralnervensystem. In: Bamberg M, Molls M, Sack H, Hrsg. Radioonkologie, Bd 2: Klinik. München-Wien-New York: Zuckschwerdt, 2004:951-1017.
37. 37. Kurtz J, Gelber R, Brady L, et al. The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1981;7:891-895 (Pubitemid 11017318)
38. 38. Lagerwaard F, Levendag P, Nowak P, et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999;43:795-803. (Pubitemid 29152652)
39. Leitlinie zur Diagnostik und Therapie der Meningeosis neoplastica der Neuro-Onkologischen Arbeitsgemeinschaft (NOA) und der Arbeitsgemeinschaft Internistische Onkologie (AIO) in der Deutschen Krebsgesellschaft (11/2005, http://www.neuroonkologie.de/fileadmin/neuroonkologie/pdf/leitmeni.pdf).
40. Lin NU, Diéras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009;15:1452-1459
41. 41. Mintz A, Kestle J, Gaspar L, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996;78:1470-1476 (Pubitemid 26317868)
42. Mintz A, Perry J, Spithoff K, et al. Management of single brain metastasis: a practice guideline. Curr Oncol 2006;14:131-143
43. 43. Murray K, Scott C, Greenberg H, et al. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys 1997;39:571-574 (Pubitemid 27441421)
44. NCCN. Clinical practice guidelines in oncology. Central nervous system cancers. V.I/2008. www.nccn.org
45. 45. Neill B, Iturria N, Link M, et al. A comparison of surgical resection and sterotactic radiosurgery in the treatment of solitary brain metastases. Int J Radiat Oncol Biol Phys 2003;55:1169-1176 (Pubitemid 36338280)
46. 46. Nieder C, Andratschke N, Grosu AL, et al. Recursive partitioning analysis (RPA) class does not predict survival in patients with four or more brain metastases. Strahlenther Onkol 2003;179:16-20. (Pubitemid 36114331)
47. 47. Noordijk E, Vecht C, Haaxma-Reiche H, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994;29:711-717 (Pubitemid 24241310)
48. Park IH, Ro J, Lee KS, et al. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann Oncol 2009;20:56-62.
49. 49. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases of the brain. JAMA 1998;280:1485-1489 (Pubitemid 28507400)
50. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322: 494-500.
51. 51. Rades D, Dunst J, Schild SE. A new scoring system to predicting the survival of patients treated with whole-brain radiotherapy for brain metastases. Strahlenther Onkol 2008;184:251-255 (Pubitemid 351572841)
52. Rades D, Kueter J-D, Hornung D, et al. Comparison of stereotactic radiosurgery (SRS) alone and whole brain radiotherapy (WBRT) plus a stereotactic boost (WBRT + SRS) for one to three brain metastases. Strahlenther Onkol 2008;184:655-662
53. Rades D, Kueter J-D, Pluemer A, et al. A matched-pair analysis comparing whole-brain radiotherapy plus stereotactic radiosurgery versus surgery plus whole-brain radiotherapy and a boost to the metastatic site for one or two brain metastases. Int J Radiat Oncol Biol Phys 2009;73:1077-1081
54. Rades D, Kueter J-D, Veninga T, et al. Whole brain radiotherapy plus stereotactic radiosurgery (WBRT+SRS) versus surgery plus whole brain radiotherapy (OP+WBRT) for 1-3 brain metastases: result of a matched pair analysis. Eur J Cancer 2009;45:400-404
55. 55. Rogers LR, Remer SE, Tejwani S. Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy. Neuro Oncol 2004;6:63-64 (Pubitemid 38139641)
56. 56. Sanghavi S, Miranpuri S, Chappell R, et al. Radiosurgery for patients with brain metastasis: a multiinstitutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys 2001;51:426-434 (Pubitemid 32884288)
57. Sautter-Bihl ML, Budach W, Dunst J, et al. DEGRO practical guidelines for radiotherapy of breast cancer I. Breast-conserving therapy. Strahlenther Onkol 2007;183:661-666
58. Sautter-Bihl ML, Souchon R, Budach W, et al. DEGRO practical guidelines for radiotherapy of breast cancer II. Postmastectomy radiotherapy, irradiation of regional lymphatics, and treatment of locally advanced disease. Strahlenther Onkol 2008;184:347-353
59. 59. Schouten LJ, Rutten J, Huveneers HA, et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002;15;94:2698-2705 (Pubitemid 34478086)
60. Shields CB, Shields LBE, Raque H Jr. Neurologic aspects of breast cancers. In: Donegan WL, Spratt JS, eds. Cancer of the breast, 5th edn. Philadelphia-London-New York-St. Louis-Sydney-Toronto: Saunders, 2002: 887-900.
61. 61. Sneed P, Suh J, Goetsch S, et al. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys 2002;53:519-526 (Pubitemid 34626488)
62. 62. Soffietti R, Cornu P, Delattre JY, et al. EFNS guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. Eur J Neurol 2006;13:674-681 (Pubitemid 44139367)
63. Souchon R, Wenz F, Sedlmayer F, et al.DEGRO practice guidelines for palliative radiotherapy of metastatic breast cancer. Bone metastases and metastatic spinal cord compression (MSCC). Strahlenther Onkol 2009;185: 417-424
64. 64. Tham J-L, Sexton K, Kramer R, et al. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006;107:696-704. (Pubitemid 44232661)
65. Tsao MN, Lloyd NS, Wong RK, et al. Clinical practice guideline on the optimal radiotherapeutic management of brain metastases. BMC Cancer 2005;34:1471-2407/5/34.
66. 66. Tsao MN, Lloyd NS, Wong RK, et al. Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. Cancer Treat Rev 2005;31:256-273 (Pubitemid 41001674)
67. Vecht C, Haaxma-Reiche H, Noordijk E, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993;33:583-590
68. Vecht C, Hovestadt A, Verbiest H, et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastasic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 1994;44: 675-680
69. Viani GA, Castilho MS, Salvajoli JV, et al. Whole brain radiotherapy for brain metastases from breast cancer: estimation of survival using two stratification systems; BMC Cancer 2007;7:53.
70. Walbert T, Gilbert MR. The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. Int J Clin Oncol 2009;14:299-306.
71. 71. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982;49:759-772 (Pubitemid 12165435)
72. 72. Wong W, Schild S, Sawyer T, et al. Analysis of outcome in patients reirradiated for brain metastases. Int J Radiat Oncol Biol Phys 1996;3:585-590 (Pubitemid 26069189)